Activity Overview
This educational activity is an archive of the live presentation held on July 17, 2026.
Target Audience
This activity is directed toward retina specialists, comprehensive ophthalmologists, and other eye care professionals involved in the treatment of neovascular retinal disease including nAMD, DME, and RVO.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Interpret extension data from clinical trials to evaluate the long-term durability profile of next-generation anti-VEGF agents in nAMD, DME, and DR, including the proportion of patients achieving extended dosing intervals beyond every 12 weeks.
- Apply clinical trial data to develop evidence-based extended-interval dosing strategies for patients with macular edema following RVO.
- Formulate individualized treatment selection and switching decisions using current comparative evidence, real-world outcomes, and label-supported dosing flexibility for patients across the spectrum of neovascular retinal disease.
Judy E. Kim, MD, FARVO, FASRS
Jean and Tom Walter Distinguished Chair in Ophthalmology in Honor of James P.
McCulley, MD
Professor, Vitreoretinal Surgery and Diseases
Vice-Chair of Education
Medical Director of Clinical Research
University of Texas Southwestern Medical Center
Dallas, TX
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Adverum, Alcon, Apellis, Astellas, Bausch & Lomb, BVI, EyePoint, Genentech/Roche, Harrow, Neurotech, Regeneron; Grant/Research Funding (to institution): Genentech, Regeneron
Anat Loewenstein, MD, MHA
VP, Ambulatory Services
Head of Retina, Ophthalmology Division
Tel Aviv Medical Center
Fox Chair in Ophthalmology
Tel Aviv University
Tel Aviv, Israel
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: 4DMT, AbbVie, Astellas, Bayer, Boehringer Ingelheim, EyePoint, Ocular Therapeutix, Oculis, Revenio, Roche, Voiant; Ownership interests in publicly traded companies: Revenio; Ownership interests in privately held companies: Notal Vision (All of these relationships have ended)
Deepak Sambhara, MD, FASRS
Partner, Medical Director of Research
Eye Clinic of Wisconsin
Adjunct Assistant Professor
Medical College of Wisconsin
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: 4DMT, AbbVie, Alcon, Adverum, Alkeus, Annexon, ANI, Apellis, Astellas, EyePoint, Genentech, Ocular Therapeutix, Opthea, Regeneron, ThermoFisher Scientific, Topcon; Grant/Research Funding (to institution): 4DMT, Adverum, Annexon, EyePoint, Kodiak, Ocular Therapeutix; Ownership interests in privately held companies: RevOpsis, Eclipse Life Sciences
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This accredited continuing education activity was planned in accordance with the ACCME Standards for Integrity and Independence to ensure balance, objectivity, independence, and scientific rigor. Faculty were instructed to use generic names when possible and to base recommendations on the best available evidence. Proprietary product names may be referenced in clinical discussion for educational purposes only and do not imply endorsement.
This activity may include discussion of investigational, unapproved, or off‑label uses of drugs or devices. Learners are advised to consult prescribing information for products discussed. Content is provided for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Learners are encouraged to critically evaluate the information presented and apply their own clinical judgment.
The views expressed are those of the individual faculty members and do not necessarily reflect the views of the accredited provider or any entity providing commercial support.
This activity may have used AI-assisted tools to support educational development. All content was reviewed and approved by qualified faculty or planners. The accredited provider retains full responsibility for accuracy, balance, and independence.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
